ADRB2 Cancer Research Results

ADRB2, β2-AR,B2AR, Adrenoceptor Beta 2; β2-Adrenergic Receptor: Click to Expand ⟱
Source:
Type:

ADRB2 (Adrenoceptor Beta 2; β2-Adrenergic Receptor) — G-protein-coupled receptor activated primarily by epinephrine and norepinephrine. ADRB2 couples mainly to Gs proteins, stimulating adenylyl cyclase, increasing intracellular cAMP, and activating PKA and downstream transcriptional and signaling pathways.

Typical modulation in cancer: Frequently tumor-promoting when chronically activated. Increased ADRB2 signaling can support proliferation, angiogenesis, migration, invasion, epithelial-mesenchymal transition, stress adaptation, immune modulation, and metastatic behavior in several cancers. Effects remain tumor- and context-dependent.

Typical mechanistic relationship: Epinephrine / norepinephrine → ADRB2 activation → Gs → adenylyl cyclase ↑ → cAMP ↑ → PKA and CREB signaling ↑, with additional MAPK, PI3K/AKT, and β-arrestin-dependent signaling.

Beta-blocker relevance: Nonselective beta blockers such as propranolol inhibit ADRB2 as well as ADRB1. In cancer studies, inhibition of ADRB2-mediated stress signaling is one proposed mechanism for the anticancer effects of beta blockers.
Scientific Papers found: Click to Expand⟱
9113- PRO,    Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers
- Review, Var, NA
ADRB2↓, Risk↓, other⇅, TumMeta↓, Inflam↓, angioG↓, EGFR↓, COX2/PTGS2↓, VEGF↓, Hypoxia↓, BloodF⇅, RadioS↑, PD-1↓, Synergy↓,
9114- PRO,    Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent
- Review, Var, NA
ADRB2↓, TumCP↓, TumCI↓, Imm↑, angioG↓, BioAv↑, Half-Life↝, BBB↑, BioAv↝, MMP2↓, MMP9↓, VEGF↓,
9115- PRO,    Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial
- Trial, BC, NA
Dose↝, Snail↓, Slug↓, NF-kB↓, ADRB2↓, TumMeta↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Kinase & Signal Transduction(tgid=6) ⓘ

EGFR↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other⇅, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCP↓, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP9↓, 1,   Slug↓, 1,   Snail↓, 1,   TumCI↓, 1,   TumMeta↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   Hypoxia↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   Imm↑, 1,   Inflam↓, 1,   NF-kB↓, 1,   PD-1↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ADRB2↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 1,   Dose↝, 1,   Half-Life↝, 1,   RadioS↑, 1,   Synergy↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BloodF⇅, 1,   EGFR↓, 1,  

Functional Outcomes(tgid=23) ⓘ

Risk↓, 1,  
Total Targets: 28

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ADRB2, β2-AR,B2AR, Adrenoceptor Beta 2; β2-Adrenergic Receptor
3 Propranolol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1923  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page